Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant hypofractionated radiotherapy versus chemotherapy combined with camrelizumab in stage III non-small cell lung cancer
ChiCTR2200061624Phase 2Recruiting
- Sponsor
- Department of Oncology, Affiliated Hospital of Southwest Medical University
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Department of Oncology, Affiliated Hospital of Southwest Medical University. Primary endpoint: Major pathological remission. Started Jun 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061624.